Rank #1965GALT

Galectin Therapeutics Inc.

$2.93

3.90% (Daily)

Market Cap

$188.92M

Revenue

$N/A

Rank by MCap

#1965

Sector

Healthcare

Industry

Biotechnology

CEO

Mr. Joel Lewis CPA

Headquarters

Norcross, GA

Employees

About Galectin Therapeutics Inc.

Galectin Therapeutics Inc., a clinical stage biopharmaceutical company, engages in the drug research and development to create new therapies for fibrotic, cancer, and other diseases. Its lead product candidate is belapectin (GR-MD-02), a galectin-3 inhibitor, which is in Phase 2b/3 clinical trial to prevent esophageal varices in patient with non-alcoholic steatohepatitis cirrhosis; and Phase 2 clinical trial for the treatment of liver fibrosis, as well as severe skin disease, and melanoma and...